Search results for nycomed
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U.S. launch of an own generic version of PR
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed is about to establish its own marketing and sales organisation in Venezuela. With this, the company will operate from an own subsidiary in all four leading Latin American pharmaceutical marke
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed successfully completed the acquisition of BradleyPharmaceuticals, a company focused on niche therapeutic markets in the United States. Bradley will be integrated into the US specialty busines
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
In 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last year to a total of € 1,222.2 million. The strong performance was accompanied in the fourth quarter by major advancements in the US
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (A
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
In the first quarter of 2008, Nycomed’s adjusted EBITDA increased by 6.2% to € 304.0 million compared to € 286.3 million in the first quarter of 2007, benefiting from the cost decreasing effects of l
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed agreed with 4SC on the sale of a major part of Nycomed's R&D projects in the field of oncology. Eight projects in the preclinical and first clinical stage will be transferred to 4SC. The agr
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities.
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
In the first six months of 2008, Nycomed’s adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effect
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed has announced a new strategy for its European manufacturing network. The company will focus its European production at five dedicated centres of competence and five facilities for regional su
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
« previous1 next »
